Life sciences

Customized approach.

Our team’s depth of clinical, scientific and consulting experience enables us to generate valuable insights across all sectors of the life sciences industry.

Insights that can help move your organization forward and meet current challenges with financial and strategic success. Over the past 20 years, we have built strong relationships with clients across the life sciences industry.

We utilize our talented and global network of life sciences-focused professionals to help you not only realize growth opportunities but also drive innovative strategies across all divisions of your business.


What we do


We know that implementing a strong and sustainable business strategy requires robust support throughout the entire product life cycle, from early development to launch and post-launch. Our full-service offerings include strategy development and business planning, competitive assessment, due diligence, deal execution advice and alliance management advice.

We employ a broad range of experience, from corporate and investment strategy to transaction evaluation and value creation.

  • Corporate strategy: We can help with data-rich activities such as competitive analysis and economic forecasting, market-size identification and analysis, growth rates and drivers, new entrants, and new products and services.
  • Brand and investment strategy: Finding and prioritizing opportunities to grow in this industry is paramount to find value. We work with our life sciences clients to develop market-entry strategies, provide market due diligence and perform strategic option assessments and portfolio optimization analysis.
  • Transaction evaluation: We help our clients by assisting with target identification and prioritization, commercial due diligence and divestiture preparation.
  • Value creation: With a critical eye, we work alongside our clients to evaluate current value drivers and opportunities for improvement. Our industry resources work with clients in areas such as brand audits, marketing mix effectiveness, sales force effectiveness, product strategies, post-merger integrations and cost optimization.

We provide data-driven insights that help clients build pragmatic strategies that deliver results.


When it comes to transactions in the life sciences industry, our clients consist of traditional corporations, as well as private equity firms and their portfolio businesses.

  • Corporate clients: Transactions are part of every company’s strategy for growth and maximizing value. Clients considering mergers, acquisitions and divestitures look to us to help manage capital strategically and execute transactions in the evolving life sciences industry. Be it strict commercial due diligence or M&A strategy, this is part of our core suite of strategic services.
  • Private equity clients: Our deep life sciences knowledge, along with our capabilities assisting private equity clients across the deal life cycle, makes us the advisor of choice to help companies make the right investments.
    Learn more

Our team brings both deep industry knowledge and experience from a myriad of transactions.

Sector experience

Navigating the life sciences landscape requires a suite of industry professionals – ranging from scientists to clinicians and consultants. With this blend of perspectives, along with more than two decades of industry relationships, our team can tap into targeted resources and provide insightful, innovative services for clients across all sectors. Our experience spans the public and private sector, as well as every major therapeutic area.

  • Pharmaceuticals and biotechnology: As life sciences technology advances, so do the opportunities for business success. From identifying new pillars of excellence, pipeline strategies, commercial readiness assessment and go-to market strategies, and lifecycle management strategies, our extensive experience in the industry allows us to accurately translate emerging science and evolving regulatory and reimbursement trends into actionable strategies.
  • Diagnostics: From start-ups to established companies, our Life Sciences practice can help clients succeed through our years of industry experience developing creative and actionable strategies. We match health care delivery trends to outreach questions to find opportunities for advancement, in areas such as outreach divestiture, market access and service expansion, adoption of emerging technologies and lab optimization.
  • Medical devices: We work with clients to identify opportunities from a client, competitor and customer perspective. As medical technology advances at breakneck speed, our team of invested professionals allows us to work with clients to develop compelling strategies and value propositions throughout the entire product life cycle.
  • Life sciences tools: Our multi-targeted approach enables our team to create effective and efficient connections throughout all stages of development, from research to tool providers. We work across industry segments, helping clients with critical issues including product strategy, corporate strategy, merger and acquisition strategy and support, customer segmentation analysis and go-to-market strategy.
  • Information technology: Health care IT sits at the nexus of two of the most rapidly growing industries, and both our life sciences and technology teams work closely together to help clients achieve commercial and clinical success.

We use our experience to help companies successfully navigate the evolving life sciences landscape.

Global reach

Worldwide, many regions struggle to lay the foundations for a functioning health care system. A lack of basic necessities, extreme poverty and insufficient infrastructure all limit access to quality, affordable health care.

Despite significant obstacles, the world is undergoing rapid transformation. Economic conditions are improving, infrastructure is developing, and access to technology and the internet is unprecedented. With this advancement comes a new set of challenges and opportunities. Traditional emerging nation complications are increasingly well-controlled, and diseases that already plague developed nations such as diabetes and cancer are rising at alarming rates.

At EY-Parthenon Life Sciences, we advise companies, investors, institutions and governments worldwide on bringing innovative therapies, diagnostics, devices and services to patients and help them transform their health care systems in ways that are customized to their populations and the unique struggles they face. For more information, please contact our EY‑Parthenon life sciences leaders worldwide.

Worldwide, regions struggle to lay the foundations for a functioning health care system. We work with our clients to help them address their systems and the unique struggles they face.

Featured events

Our people

Case study: Due diligence for Private Equity firm


One of Parthenon’s private equity firm clients was interested in purchasing a manufacturer of articulating ladders, sold nationally through major hardware and home improvement stores.

Parthenon was tasked with answering the private equity client’s key questions in order to confirm or deny its investment thesis. Those questions included the following:

  • What are the key dynamics of the ladder market, including size, growth and segmentation?
  • What is the competitive landscape of the ladder market and how is it changing?
  • How do the channel and end-users view the product and why do they choose it over other options?
  • What additional growth opportunities exist for the target company?

Parthenon EY Action

During the six-week engagement, Parthenon used extensive primary and secondary research efforts to determine the product’s position within key retailers as well as its market penetration. Specifically, Parthenon executed interviews with several key constituencies including:

  • Management team members
  • Consumers (ladder owners, articulating ladder owners, and non-ladder owners)
  • Professionals (contractors, electricians, and painters)
  • Retailers buyers, Big Box, franchise hardware, and independent hardware competitors
  • Industry sources


Based on the outcome of Parthenon’s work, the private equity client ultimately decided not to purchase the target company.